



16C1
3/22

1632 WD
FEB 24 2000
Box Seq
13/B
B. Webb
4-12-00

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

By Valerie A. Wilson ELI LILLY AND COMPANY Date February 17, 2000

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :	Thomas Frank Bumol, et al.)	
)	
Serial No. :	09/280,567)	Attention:
)	Branch Manager
Filed:	March 30, 1999)	
)	
For:	THERAPEUTIC APPLICATIONS OF)	
	mFLINT POLYPEPTIDES)	
)	
Docket No. :	X-12915)	

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents
 Washington, D. C. 20231
 Attention: Box Sequence
 Sir:

This is in response to a "Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures" dated February 8, 2000, noting the absence of an acceptable Sequence Listing.

Enclosed herewith are:

- 1) a copy of the Notice;
- 2) a computer-readable copy of the Sequence Listing pursuant to 37 C.F.R. § 1.821(e);
- 3) a paper copy of the Sequence Listing pursuant to 37 C.F.R. § 1.821(c);
- 4) an affirmation pursuant to 37 C.F.R. § 1.821(f); and

FEB 29 2000

TECH CENTER 1600/2900

Serial No. 09/280,567

- 5) a Preliminary Amendment amending the
specification to include the sequence listing.

Respectfully submitted,



Thomas D. Webster
Attorney for Applicants
Registration No. 39,872
Phone: 317-276-3334

Eli Lilly and Company
Patent Division/TDW
Lilly Corporate Center
Indianapolis, Indiana 46285

February 16, 2000